Back

State of the Art - Novel targets in anti thrombotic drug development

1 September 2019 (16:40 - 16:58)
Organised by:
Congress Presentation Part of: New developments in anti thrombotic drug therapy Risk Factors and Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

3 More presentations in this session

Presentation thumbnail
Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin
Assistant Professor C. Koh (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
Professor R. Storey (Sheffield, GB)
Abstract Slides Video
Presentation thumbnail
Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452
Professor L. Jennings (Memphis, US)
Abstract Slides Video

Access the full session

Session thumbnail
New developments in anti thrombotic drug therapy

The Event

Event poster

ESC Congress 2019

1 September 2019 16:40 CET
You may be interested in
thumbnail
Congress Session
How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?
27 August 2023
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Presentation
S1P receptor-1 signaling reduces arterial thrombosis by upregulation of endothelial thrombomodulin expression
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources